211 related articles for article (PubMed ID: 31379581)
1. Comparison of Different Liver Test Thresholds for Drug-Induced Liver Injury: Updated RUCAM versus Other Methods.
Yang H; Guo D; Xu Y; Zhu M; Yao C; Chen C; Jia W
Front Pharmacol; 2019; 10():816. PubMed ID: 31379581
[TBL] [Abstract][Full Text] [Related]
2. Marked Increase of Gamma-Glutamyltransferase as an Indicator of Drug-Induced Liver Injury in Patients without Conventional Diagnostic Criteria of Acute Liver Injury.
Weber S; Allgeier J; Denk G; Gerbes AL
Visc Med; 2022 Jun; 38(3):223-228. PubMed ID: 35814980
[TBL] [Abstract][Full Text] [Related]
3. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.
Robles-Diaz M; Lucena MI; Kaplowitz N; Stephens C; Medina-Cáliz I; González-Jimenez A; Ulzurrun E; Gonzalez AF; Fernandez MC; Romero-Gómez M; Jimenez-Perez M; Bruguera M; Prieto M; Bessone F; Hernandez N; Arrese M; Andrade RJ; ; ;
Gastroenterology; 2014 Jul; 147(1):109-118.e5. PubMed ID: 24704526
[TBL] [Abstract][Full Text] [Related]
4. Liver Injury in COVID-19 Patients with Drugs as Causatives: A Systematic Review of 996 DILI Cases Published 2020/2021 Based on RUCAM as Causality Assessment Method.
Teschke R; Méndez-Sánchez N; Eickhoff A
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563242
[TBL] [Abstract][Full Text] [Related]
5. Roussel Uclaf Causality Assessment Method for Drug-Induced Liver Injury: Present and Future.
Danan G; Teschke R
Front Pharmacol; 2019; 10():853. PubMed ID: 31417407
[TBL] [Abstract][Full Text] [Related]
6. The Indian Network of Drug-Induced Liver Injury: Etiology, Clinical Features, Outcome and Prognostic Markers in 1288 Patients.
Devarbhavi H; Joseph T; Sunil Kumar N; Rathi C; Thomas V; Prasad Singh S; Sawant P; Goel A; Eapen CE; Rai P; Arora A; Leelakrishnan V; Gopalakrishnan G; Vardhan Reddy V; Singh R; Goswami B; Venkataraman J; Balaraju G; Patil M; Patel R; Taneja S; Koshy A; Nagaraja Rao P; Kumar Sarin S; Rathi P; Dhiman R; Duseja AK; Vargese J; Kumar Jain A; Wadhawan M; Ranjan P; Karanth D; Ganesh P; Nijhawan S; Krishna Dhali G; Adarsh CK; Jhaveri A; Nagral A; Rao P; Shalimar
J Clin Exp Hepatol; 2021; 11(3):288-298. PubMed ID: 33994711
[TBL] [Abstract][Full Text] [Related]
7. A revised electronic version of RUCAM for the diagnosis of DILI.
Hayashi PH; Lucena MI; Fontana RJ; Bjornsson ES; Aithal GP; Barnhart H; Gonzalez-Jimenez A; Yang Q; Gu J; Andrade RJ; Hoofnagle JH
Hepatology; 2022 Jul; 76(1):18-31. PubMed ID: 35014066
[TBL] [Abstract][Full Text] [Related]
8. Utility of Lymphocyte Transformation Test for Assisting Updated Roussel Uclaf Causality Assessment Method in Drug-Induced Liver Injury: A Case-Control Study.
Rodríguez A; García-García I; Martínez de Soto L; Gómez López De Las Huertas A; Borobia AM; González-Torbay A; Akatbach-Bousaid I; González-Muñoz M; Ramírez E
Front Pharmacol; 2022; 13():819589. PubMed ID: 35370653
[No Abstract] [Full Text] [Related]
9. Idiosyncratic Drug-Induced Liver Injury (DILI) and Herb-Induced Liver Injury (HILI): Diagnostic Algorithm Based on the Quantitative Roussel Uclaf Causality Assessment Method (RUCAM).
Teschke R; Danan G
Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33800917
[TBL] [Abstract][Full Text] [Related]
10. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method.
Rockey DC; Seeff LB; Rochon J; Freston J; Chalasani N; Bonacini M; Fontana RJ; Hayashi PH;
Hepatology; 2010 Jun; 51(6):2117-26. PubMed ID: 20512999
[TBL] [Abstract][Full Text] [Related]
11. Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019.
Teschke R
Front Pharmacol; 2019; 10():730. PubMed ID: 31396080
[TBL] [Abstract][Full Text] [Related]
12. Advances in Idiosyncratic Drug-Induced Liver Injury Issues: New Clinical and Mechanistic Analysis Due to Roussel Uclaf Causality Assessment Method Use.
Teschke R; Danan G
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446036
[TBL] [Abstract][Full Text] [Related]
13. Outcomes and Predictors of Mortality in Patients With Drug-Induced Liver Injury at a Tertiary Hospital in South India: A Single-Centre Experience.
Sunil Kumar N; Remalayam B; Thomas V; Ramachandran TM; Sunil Kumar K
J Clin Exp Hepatol; 2021; 11(2):163-170. PubMed ID: 33746440
[TBL] [Abstract][Full Text] [Related]
14. An analysis of silybin meglumine tablets in the treatment of drug-induced liver injury as assessed for causality with the updated Roussel Uclaf Causality Assessment Method using a nationwide database.
Zhang B; Jiang G; Wang L; Li X; Zhao C; Tan Q; Kang W; Feng Y; Han X; Raza HK; Mao Y
Br J Clin Pharmacol; 2023 Apr; 89(4):1329-1337. PubMed ID: 36278948
[TBL] [Abstract][Full Text] [Related]
15. Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: A retrospective analysis.
Swanson LA; Kassab I; Tsung I; Schneider BJ; Fontana RJ
Front Oncol; 2022; 12():984940. PubMed ID: 36353563
[TBL] [Abstract][Full Text] [Related]
16. Preliminary Results of a Novel Algorithmic Method Aiming to Support Initial Causality Assessment of Routine Pharmacovigilance Case Reports for Medication-Induced Liver Injury: The PV-RUCAM.
Scalfaro E; Streefkerk HJ; Merz M; Meier C; Lewis D
Drug Saf; 2017 Aug; 40(8):715-727. PubMed ID: 28508325
[TBL] [Abstract][Full Text] [Related]
17. Herb-induced liver injury (HILI) with 12,068 worldwide cases published with causality assessments by Roussel Uclaf Causality Assessment Method (RUCAM): an overview.
Teschke R; Eickhoff A; Schulze J; Danan G
Transl Gastroenterol Hepatol; 2021; 6():51. PubMed ID: 34423172
[TBL] [Abstract][Full Text] [Related]
18. Exploring the efficacy and safety of polyene phosphatidylcholine for treatment of drug-induced liver injury using the Roussel Uclaf causality assessment method: a propensity score matching comparison.
Lei X; Zhang J; Xu Q; Li J; Qian Y; Zhang J; Liu L; Zhong W; Wang Y; Han X; Tang J; Zeng M; Mao Y
J Int Med Res; 2021 Aug; 49(8):3000605211039810. PubMed ID: 34433332
[No Abstract] [Full Text] [Related]
19. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis.
Sanai FM; Babatin MA; Bzeizi KI; Alsohaibani F; Al-Hamoudi W; Alsaad KO; Al Mana H; Handoo FA; Al-Ashgar H; Alghamdi H; Ibrahim A; Aljumah A; Alalwan A; Altraif IH; Al-Hussaini H; Myers RP; Abdo AA
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1493-1499.e2. PubMed ID: 23811251
[TBL] [Abstract][Full Text] [Related]
20. Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993-Mid 2020: A Comprehensive Analysis.
Teschke R; Danan G
Medicines (Basel); 2020 Sep; 7(10):. PubMed ID: 33003400
[No Abstract] [Full Text] [Related]
[Next] [New Search]
